Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial

[1]  Y. Hsu,et al.  Association of Cardiovascular Risk With Inhaled Long-Acting Bronchodilators in Patients With Chronic Obstructive Pulmonary Disease: A Nested Case-Control Study , 2018, JAMA internal medicine.

[2]  K. Rabe,et al.  Peripheral eosinophil count as a biomarker for the management of COPD: not there yet , 2017, European Respiratory Journal.

[3]  C. Vogelmeier,et al.  GOLD 2017 treatment pathways in 'real life': An analysis of the DACCORD observational study. , 2017, Respiratory medicine.

[4]  Meilan K. Han,et al.  Frequency of Exacerbations in COPD: An Analysis of the SPIROMICS Cohort , 2017, The Lancet. Respiratory medicine.

[5]  Dave Singh,et al.  Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial , 2017, The Lancet.

[6]  S. Suissa,et al.  Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events , 2017, European Respiratory Journal.

[7]  J. Wedzicha,et al.  Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial , 2017, American journal of respiratory and critical care medicine.

[8]  C. Vogelmeier,et al.  A two-year evaluation of the 'real life' impact of COPD on patients in Germany: The DACCORD observational study. , 2017, Respiratory medicine.

[9]  Dave Singh,et al.  Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial , 2016, The Lancet.

[10]  I. Pavord,et al.  A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol , 2016, European Respiratory Journal.

[11]  J. Wedzicha,et al.  Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. , 2016, The New England journal of medicine.

[12]  M. Cazzola,et al.  Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives , 2015, Drugs.

[13]  I. Pavord,et al.  Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. , 2015, The Lancet. Respiratory medicine.

[14]  N. Leidy,et al.  Measuring respiratory symptoms of COPD: performance of the EXACT- Respiratory Symptoms Tool (E-RS) in three clinical trials , 2014, Respiratory Research.

[15]  J. Vestbo,et al.  Understanding the GOLD 2011 Strategy as applied to a real-world COPD population. , 2014, Respiratory medicine.

[16]  J. Wedzicha,et al.  Minimal clinically important differences in pharmacological trials. , 2014, American journal of respiratory and critical care medicine.

[17]  T. To,et al.  Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. , 2013, JAMA internal medicine.

[18]  N. Leidy,et al.  Patient-reported Outcome (PRO) Measures for Clinical Trials of COPD: The EXACT and E-RS , 2013, COPD.

[19]  J. Wedzicha,et al.  Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. , 2013, The Lancet. Respiratory medicine.

[20]  Marco Lodi,et al.  Inhaler mishandling remains common in real life and is associated with reduced disease control. , 2011, Respiratory medicine.

[21]  J. Wedzicha,et al.  Susceptibility to exacerbation in chronic obstructive pulmonary disease. , 2010, The New England journal of medicine.

[22]  P. Jones,et al.  Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results , 2009, European Respiratory Journal.

[23]  S. Hurd,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.